Literature DB >> 17927862

[Expression and clinical significance of TGF-beta1 and its signaling pathway proteins in nasopharyngeal carcinoma].

Rui Sun1, Ming-Yuan Chen, Jian Sun, Ying Zhang, Chang-Qing Zhang, Jing-Hui Hou, Ming-Huang Hong.   

Abstract

BACKGROUND &
OBJECTIVE: Transforming growth factor beta (TGF-beta) has various biological functions, and plays important roles in cell proliferation, differentiation and apoptosis. This study was to investigate the expression and clinical significance of TGF-beta1 and its signaling pathway proteins (TGF-beta1 receptors TGFbetaRI and TGFbetaRII, cytoplasmic mediator Smad4) in nasopharyngeal carcinoma (NPC).
METHODS: The expression of TGF-beta1, TGFbetaRI, TGFbetaRII, and Smad4 in 91 specimens of NPC was detected by SP immunohistochemistry. Their correlations to local relapse, distant metastasis and survival rate of the patients were analyzed.
RESULTS: The positive rates of TGF-beta1, TGFbetaRI, TGFbetaRII and Smad4 were 69.2%, 73.6%, 62.6% and 72.5% in NPC. The differences in the positive rates of TGF-beta1 (0, 12.7%, 50.8%, and 36.5%) and TGFbetaRII (0, 15.8%, 54.4%, and 29.8%) among stageI, II, III and IV NPC were significant (P<0.05). However, there was no significant difference in the expression of TGFbetaRI and Smad4. The local relapse rate was significantly higher and 5-year overall survival rate was significantly lower in TGF-beta1-positive patients than in TGF-beta1-negative patients (22.2% vs. 3.6%, P<0.05û 63.5% vs. 82.1%, P<0.05). All the 4 proteins had no correlation to the distant metastasis of NPC (P>0.05).
CONCLUSION: Autocrine TGF-beta1 exists in NPC patients, which is correlated to the local relapse and survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17927862

Source DB:  PubMed          Journal:  Ai Zheng


  1 in total

1.  Epstein-Barr virus encoded microRNA BART7 regulates radiation sensitivity of nasopharyngeal carcinoma.

Authors:  Wei Gao; Zeng-Hong Li; Siqi Chen; Jimmy Yu-Wai Chan; Min Yin; Min-Juan Zhang; Thian-Sze Wong
Journal:  Oncotarget       Date:  2017-03-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.